Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03190213
Title Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma (Pembro NEC)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Utah
Indications

neuroendocrine carcinoma

Therapies

Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.